Measuring a blood marker and lung function in people with cystic fibrosis

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers with cystic fibrosis (CF) whose lung function is reduced. It tests a quality improvement plan to raise lung function over 12 months.

Age

6 years or older

Sex

All sexes

Disease stage

Reduced lung function: FEV₁ of 80% or less

Biomarker or test result

CF confirmed by a positive sweat chloride test (60 milliequivalent/L or more) and/or two CF disease-causing gene mutations

Main reasons for not taking part

• Cannot do spirometry (a lung function breathing test)

The registry criteria, word for word

What the trial wants to find out

To implement a quality improvement plan aimed at achieving a 5% increase in the Forced expiratory volume in 1st second (FEV1) (% predicted value) in cystic fibrosis (CF) patients with impaired pulmonary function parameters over 12 months. Additionally, the plan aims to measure serum human epididymis protein 4 (HE4) levels in the studied subjects before and after pulmonary function improvement.

The group in the trial

• Pediatric CF patients aged 6 years and above with an FEV₁% predicted below 80%.

  Using quality improvement principles for patient care and reassessing after one year.